1:00 |
284 |
Hero |
Is a “Wait and See” Strategy Justified in Localised Neuroblastoma in Infancy? |
1:15 |
285 |
Strother |
Surgery Alone or Followed by Chemotherapy for Patients with Stages 2A and 2B Neuroblastoma: Results of Children's Oncology Group Study P9641 |
1:30 |
286 |
Di Cataldo |
First European Neuroblastoma Study (99.3 Trial) for Infants with Bone, CNS, or Pleura/Lung Metastases and No MYCN Amplification |
1:45 |
287 |
Canyete |
MYCN Amplified Neuroblastoma in Infants. Final Results of 99,4 Trial |
2:00 |
288 |
Monclair |
The International Neuroblastoma Risk Group (INRG) Staging System - INRGSS A New Staging System To Be Included in the INRG Classification System |
2:15 |
289 |
Simon |
Surgical Risk Factors (SRG) Cannot Substitute INSS Staging in Localized Neuroblastoma |
2:30 |
290 |
Ambros |
International Consensus for Neuroblastoma Molecular Diagnostics: Report from the International Neuroblastoma Risk Grouping (INRG) Biology Committee |
2:45 |
291 |
Ernestus |
Incidence and Prognosis of Undifferentiated and Poorly Differentiated Neuroblastoma According to International Neuroblastoma Pathology Committee Classification |
3:00 |
292 |
Ikegaki |
The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma |
3:15 |
293 |
Ikematsu |
Prediction of the Prognosis of Neuroblastomas by Blood Level of the Growth Factor Midkine |
3:30 |
294 |
Egler |
Correspondence of IL-6 Levels to Disease Extent in Neuroblastoma |
3:45 |
295 |
Raguenez |
ppGalNAc-T13: A New Molecular Marker of Bone Marrow Involvement in Neuroblastoma |
4:00 |
Break |
|
|
